Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel
Moldiag Erkrankungen Gene Support Kontakt

PCSK9-Gen

Das PCSK9-Gen kodiert ein Protein, welches für die Regulation der LDL-Rezeptoraktivität mitverantwortlich ist. Mutationen verursachen eine autosomal dominante Form der familiären Hypercholesterinämie.

Genstruktur

Das Protein, welches durch das PCSK9-Gen kodiert wird spielt eine wichtige Rolle bei der Regulation des LDL-Rezeptors auf der Oberfläche von Hepatozyten. Mutationen führen zur autosomal dominanten Hypercholesterinämie vom Typ 3.

Gentests:

Klinisch Untersuchungsmethoden Familienuntersuchung
Bearbeitungszeit 5 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 25 Tage
Probentyp genomische DNS

Verknüpfte Erkrankungen:

Autosomal dominante Hypercholesterinämie 3
PCSK9
Kombinierte familiäre Hyperlipämie mit gestörter LDL-Clearance
ATF6
LDLR
PCSK9

Referenzen:

1.

Kathiresan S et al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events.

external link
2.

Kotowski IK et al. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

external link
3.

Rashid S et al. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

external link
4.

Sun XM et al. (2005) Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia.

external link
5.

Maxwell KN et al. (2005) Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

external link
6.

Park SW et al. (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

external link
7.

Ouguerram K et al. (2004) Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

external link
8.

Maxwell KN et al. (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

external link
9.

Shioji K et al. (2004) Genetic variants in PCSK9 affect the cholesterol level in Japanese.

external link
10.

Seidah NG et al. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.

external link
11.

Cohen J et al. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

external link
12.

Timms KM et al. (2004) A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.

external link
13.

Abifadel M et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

external link
14.

Hunt SC et al. (2000) Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred.

external link
15.

Varret M et al. (1999) A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32.

external link
16.

Kathiresan S et al. (2008) A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction.

external link
17.

Schmidt RJ et al. (2008) Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

external link
18.

Kwon HJ et al. (2008) Molecular basis for LDL receptor recognition by PCSK9.

external link
19.

Mayne J et al. (2007) Plasma PCSK9 levels correlate with cholesterol in men but not in women.

external link
20.

Benjannet S et al. (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.

external link
21.

Zhao Z et al. (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

external link
22.

Lambert G et al. (2006) Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

external link
23.

Cohen JC et al. (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

external link
24.

Teslovich TM et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids.

external link
25.

NCBI article

NCBI 255738 external link
26.

OMIM.ORG article

Omim 607786 external link
27.

Orphanet article

Orphanet ID 124137 external link
28.

Wikipedia Artikel

Wikipedia DE (PCSK9) external link
Update: 14. August 2020
Copyright © 2005-2020 Zentrum für Nephrologie und Stoffwechsel, Dr. Mato Nagel
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Deutschland, Tel.: +49-3576-287922, Fax: +49-3576-287944
Seitenüberblick | Webmail | Haftungsausschluss | Datenschutz